GlassScriptPhysician profile
Hope Havener
NPI 1639173495
$16,996.16
in general payments reported to CMS, 2019-2025
52 companies · $2,743 in 2025
The $2,743 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,257 · 2020: $2,029 · 2021: $2,262 · 2022: $2,429 · 2023: $2,874 · 2024: $2,402 · 2025: $2,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,897 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,897.47 |
| Education | $122.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,281.89 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $1,474.67 | 2019-2025 | Repatha, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,281.62 | 2019-2025 | Jardiance |
| Abbvie INC. | $1,275.57 | 2019-2025 | |
| Lilly USA, LLC | $1,165.19 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $1,151.02 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,048.96 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $934.93 | 2021-2025 | |
| Glaxosmithkline, LLC. | $855.72 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $796.28 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Amarin Pharma, INC. | $705.24 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $280.60 | 2020-2023 | Livalo, Seglentis |
| Phathom Pharmaceuticals, INC. | $238.68 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $230.35 | 2019-2025 | Veozah |
| Sumitomo Pharma America, INC. | $227.83 | 2024-2025 | Gemtesa |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hope Havener listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.